A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects

NCT00783003 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK233705 and GW642444
DRUG: GW642444
DRUG: GSK233705
DRUG: Placebo

Sponsor

GlaxoSmithKline